Verrica Pharmaceuticals (VRCA) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free VRCA Stock Alerts $6.65 -0.14 (-2.06%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVerrica Pharmaceuticals Inc (VRCA)investing.com - April 19 at 7:13 PMNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)marketbeat.com - April 10 at 8:24 AMVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conferencemsn.com - April 4 at 11:15 AMStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossfinance.yahoo.com - April 3 at 8:23 AMVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protectionmsn.com - March 31 at 11:37 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAfinanznachrichten.de - March 28 at 3:45 PMVerrica Pharma gains as FDA lists Ycanth in Orange Bookmsn.com - March 27 at 3:42 AMVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Factsmarkets.businessinsider.com - March 26 at 8:15 AMVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAglobenewswire.com - March 26 at 7:30 AMFmr LLC Has $5.85 Million Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)marketbeat.com - March 9 at 4:22 AMVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chatmsn.com - March 3 at 10:22 PMVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 2 at 10:39 AMWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?finance.yahoo.com - March 2 at 10:39 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 11:46 PMVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Ratingmarkets.businessinsider.com - March 1 at 6:46 PMBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansionmarkets.businessinsider.com - March 1 at 6:46 PMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:45 PMVerrica Pharmaceuticals (NASDAQ:VRCA) PT Raised to $13.00marketbeat.com - March 1 at 8:28 AMVerrica Pharmaceuticals (NASDAQ:VRCA) Receives "Buy" Rating from Needham & Company LLCmarketbeat.com - March 1 at 8:28 AMBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptancemarkets.businessinsider.com - February 29 at 10:09 PMVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 12:07 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - February 29 at 7:30 AMEarnings Outlook For Verrica Pharmaceuticalsbenzinga.com - February 28 at 6:01 PMVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:30 AMVerrica Pharmaceuticals (VRCA) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - February 23 at 9:50 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024finance.yahoo.com - February 22 at 10:58 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024globenewswire.com - February 22 at 7:30 AMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Decrease in Short Interestmarketbeat.com - February 13 at 10:47 AMVerrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Tradersmsn.com - February 12 at 7:18 PM7 Potential Short-Squeeze Stocks Poised for Rapid Gainsfinance.yahoo.com - February 6 at 2:42 PMVerrica Pharmaceuticals sues Canadian drug maker, alleging false advertising and unfair competitionbizjournals.com - February 5 at 7:16 PMVerrica sues to keep unapproved cantharidin drugs off US marketmsn.com - February 5 at 2:15 PMVerrica Pharma Files Suit Against Dormer Lab Alleging False Advertising, Unfair Competitionmarkets.businessinsider.com - February 5 at 2:15 PMVerrica sues to keep unapproved catharidin drugs off US marketseekingalpha.com - February 5 at 2:15 PMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competitionfinanznachrichten.de - February 5 at 9:15 AMVerrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competitionfinance.yahoo.com - February 5 at 9:15 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Servicesfinanznachrichten.de - January 29 at 11:32 AMVerrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Servicesfinance.yahoo.com - January 29 at 11:32 AMLigand Pharma's at-home skin treatment gets FDA approvalreuters.com - January 5 at 8:27 PMVerrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinomafinance.yahoo.com - January 5 at 10:26 AMVerrica Issues Statement On Type C Meeting With FDA Regarding Development Plan For YCANTHmarkets.businessinsider.com - January 4 at 5:33 PMVerrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Wartsfinance.yahoo.com - January 4 at 12:33 PMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTHfinanznachrichten.de - January 3 at 3:57 PMVerrica Pharmaceuticals Announces Agreement With Walgreens To Distribute YCANTHmarkets.businessinsider.com - January 3 at 8:41 AMVerrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™finance.yahoo.com - January 3 at 8:41 AMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Major Shareholder Acquires $354,691.48 in Stockmarketbeat.com - December 26 at 9:16 PMDespite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownershipfinance.yahoo.com - December 24 at 9:36 AMInsider Trading: Verrica Stock (NASDAQ:VRCA) Gained on $6.9M Insider Buymsn.com - December 21 at 11:00 PMVerrica Pharmaceuticals Stock (NASDAQ:VRCA) Dividends: History, Yield and Datesbenzinga.com - December 17 at 3:12 AM Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. VRCA Media Mentions By Week VRCA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRCA News Sentiment▼0.000.39▲Average Medical News Sentiment VRCA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRCA Articles This Week▼12▲VRCA Articles Average Week Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRMD News INZY News AKBA News ERAS News TERN News XOMA News RAPT News AQST News KMDA News AVIR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRCA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
